Six Questions For Janssen Pharma Chairman Paul Stoffels
This article was originally published in The Pink Sheet Daily
Executive Summary
Amid increasing competition, the need is to be the best in collaboration with academics, and not to rely on a single regulatory agency amid regulatory delays in China, stresses Johnson & Johnson senior executive Paul Stoffels in a wide-ranging exclusive interview with PharmAsia News.
You may also be interested in...
Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.
Paradox Of China Biotech And What Lies Ahead In 2023
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.
Cold Water On Already Frozen Sector: Industry Growing Wary Of China Price Cuts
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.